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ABSTRACT For the structural analysis of T-cell receptor (TCR) and peptide/MHC interaction, a series of peptides with a single
amino acid substitution by a corresponding D-amino acid, having the same weight, size, and charge, within P18-I10 (aa318–
327: RGPGRAFVTI), an immunodominant epitope of HIV-1 IIIB envelope glycoprotein, restricted by the H-2Dd class I MHC
molecule, has been synthesized. Using those peptides, we have observed that the replacement at positions 324F, 325V, 326T,
and 327I with each corresponding D-amino acid induced marked reduction of the potency to sensitize targets for P18-I10-
speciﬁc murine CD81 cytotoxic T lymphocytes (CTLs), LINE-IIIB, recognition. To analyze further the role of amino acid at
position 325, the most critical site for determining epitope speciﬁcity, we have developed a CTL line [LINE-IIIB(325D)] and its
offspring clones speciﬁc for the epitope I-10(325v) having a D-valine (v) at position 325. Taking advantage of two distinct sets of
CD81 CTLs restricted by the same Dd, three-dimensional structural analysis on TCR and peptide/MHC complexes by molecular
modeling was performed, which indicates that the critical amino acids within the TCRs for interacting with 325V or 325v appear
to belong to the complementarity-determining region 1 but not to the complementarity-determining region 3 of Vb chain.
INTRODUCTION
Immune responses to viral infection include both humoral
and cell-mediated effector mechanisms. The major effector
cells in cellular immunity are CD8 molcule-expressing cyto-
toxic T lymphocytes (CTLs) that can recognize and kill
virus-infected cells. In general, endogenously synthesized
antigens such as virus-derived proteins are fragmented inside
of the cells and are presented on the cell in conjunction with
class I major histocompatibility complex (MHC) molecules.
Such processed epitope peptides associated with the class I
MHCmolecules can be recognized by CTLs via their speciﬁc
T cell receptors (TCRs).
The TCRs expressed on the cell surface of T lymphocytes
contain similar structural patterns with immunoglobulin-like
domains, comprising one variable and one constant, as well
as a transmembrane domain and a short cytoplasmic tail. The
speciﬁcity for T-cell recognition seems to be determined by
the variable domains, TCR Va and TCR Vb, within two
heterodimeric subsets, TCRa and TCRb. Several recent
ﬁndings have indicated that the TCRa and b heterodimers
are oriented to the long axis of the epitope-peptide/MHC
complex (1), in which the Va domain appears to cover the
amino-terminal half of the epitope peptide, whereas Vb is
located over the carboxyl-terminal portion of the epitope (2).
Among those variable Va and Vb domains, three hyper-
variable complementarity-determining regions (CDRs), termed
CDR1, CDR2, and CDR3, seem to directly interact with the
peptide/MHC complex. Because the degree of variability is
the greatest in the CDR3 loop generally, and it is positioned
more closely over the epitope peptide than other CDR1 and
CDR2 loops, the antigen speciﬁcity has been considered to
be associated with the CDR3 but not with CDR1 or CDR2,
which were predicted to interact principally with the MHC
molecules (3,4). Indeed, according to a recent report on the
murine Kb class I MHC molecule-restricted epitope octa-
peptide (pKB1: KVITFIDL) recognized by KB5-C20 TCR
(5), TCR plasticity is primarily restricted to the CDR3 loops
of the Vb domain. Nevertheless, recent crystallographic
analyses on various TCR and peptide/MHC interactions
have suggested the possibility of direct contact for both
CDR1 and CDR3 in the TCRa and TCRb chains with the
antigenic peptide/MHC complex (5,6). Therefore, to un-
derstand more precise molecular interactions determining
T-cell speciﬁcity through TCR-mediated peptide/MHC com-
plex recognition, we took advantage of the following known
materials to accomplish the analysis.
We have established CD81, H-2Dd class I MHC molecule-
restricted murine CTL line, LINE-IIIB, speciﬁc for the
envelope glycoprotein 160 (gp160) composed of;900 amino
acids derived from one of the most commonly used IIIB
strains of human immunodeﬁciency virus type-1 (HIV-1), a
causative agent for acquired immunodeﬁciency syndrome
(AIDS) (7). Then, we have identiﬁed an immunodominant
epitope within the gp160 as a 15-residue peptide, P18IIIB
(aa315–329: RIQRGPGRAFVTIGK), for the LINE-IIIB rec-
ognition (7) as well as the minimal active 10-residue peptide,
P18-I10 (aa318–327: RGPGRAFVTI) within P18IIIB (8).
Moreover, although the position of P18IIIB is located in the
hypervariable portion (termed V3 domain) of the viral en-
velope, the site has turned out to be recognized by various
isolate-speciﬁc CTLs in an isolate-speciﬁc manner (9,10), and
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a number of distinct class I MHC molecules did present the
P18IIIB to each speciﬁc CTL (11). Furthermore, the P18IIIB
in the V3-domain was found to be overlapped with the major
determinant sites for neutralizing antibodies against HIV-1 in
an isolate-speciﬁc manner (12–14) and also to be recognized
by CD4-positive helper T lymphocytes speciﬁc for HIV-1 in a
class II MHC molecule-restricted manner (8,15). In addition,
human CTLs did see the P18IIIB when presented by HLA A2
and A3 (16). These ﬁndings indicate that the P18IIIB appears
to be a highly attractive epitope for the development of pep-
tide-based vaccine against AIDS, and thus, it is important to
study the precise interaction between the epitope P18IIIB and
their speciﬁc TCRs to study the manner of T-cell-mediated
immune responses.
Using a series of peptides with an alanine (A) substitution
at each position, we observed that amino acids at positions
322R and position 324F were critical for Dd binding and that
position 325V within P18-I10 was essential for interacting
with TCRs (17). Also, C-terminus 327I appears to be critical
for Dd binding to form the Dd-binding motif (8,18). In
addition, we found the HIV-MN isolate-speciﬁc CTLs also
saw the corresponding minimal active site, MNT10 (aa318–
327: IGPGRAFYTT) in association with the same Dd mole-
cules, and replacement of just a single residue, 325V with
325Y, within the P18-I10 or vice versa within the MNT10
was sufﬁcient to reciprocally interchange the speciﬁcities for
these two non-cross-reactive sets of CTLs (9,10). Thus, a
single side chain at position 325 can play a critical role in
determining the epitope speciﬁcity within both P18-I10 and
MNT10 presented by the same class I MHC molecule Dd for
CD81 CTL TCR recognition mediated by the CDRs.
It has been reported that the charge of the amino acid
might also affect interaction between TCRs and peptide/
MHC complexes (19). Indeed, when negatively charged glu-
tamic acid (E) at position 436 within HIV-1-envelope-derived
helper T-cell epitope T1 (aa428–443; KQIINMWQEVG-
KAMYA) (20) was substituted with either uncharged alanine
(A) or size-conservative, uncharged glutamine (Q), stimula-
tory capacity of the substitute peptides for T1-speciﬁc T
hybridomas was signiﬁcantly enhanced, although charge-
conservative aspartic acid (D) substitution did not show any
enhancement (21). Moreover, substitution at position 6Q in
the immunodominant CTL epitope for vesicular stomatitis
virus (RGYVYQGL, VSV8) presented by Kd class I MHC
molecules to a negatively charged residue such as 6E or 6D
induced a change at position 93S of TCR CDR3a to a posi-
tively charged residue 93R or 93K (22). Therefore, partic-
ularly to reduce the inﬂuence of charges of each amino acid
as well as the size and molecular weight on TCR-mediated
recognition, a series of P18-I10-derived peptides with a single
amino acid substitution by D-amino acid at each correspond-
ing site have been synthesized. Using those D-amino acid–
substituted peptides, we found apparent reduction of speciﬁc
cytotoxic activity in the 325V-speciﬁc LINE-IIIB cells by
the replacement of 325V with D-type valine at position 325,
represented as I10(325v). Then, we attempted to establish
CTL lines speciﬁc for the epitope I-10(325v) by immuniza-
tion with dendritic cells pulsed with the peptide, I10(325v)
(23). We have successfully generated both a 325(v)-speciﬁc
CTL line and clones that did not cross-react with the original
P18-I10.
Taking advantage of two distinct sets of CD81 CTL
clones speciﬁc for either P18-I10 bearing L-type valine or
I10(325v) having D-type valine at position 325 presented by
the same MHC molecules Dd, we attempted to study the
three-dimensional (3D) structural analysis on TCRs and
peptide/MHC complexes. Here, using molecular modeling
analysis, we would like to show that the critical amino acids
for interacting with P18-I10 in determining epitope speci-
ﬁcity appear to be the peptide DMSHET within CDR1 of
Vb7, whereas those for interacting with I10(325v) appear to
be TNSHNY within CDR1 of Vb8.3.
MATERIALS AND METHODS
Mice
Female BALB/c (H-2d) mice were purchased from Charles-River Japan Inc.
(Tokyo, Japan). The mice were 6 to 10 weeks of age and were maintained
in a speciﬁc-pathogen-free environment. All experiments were performed
according to the guidelines of the NIH Guide for the Care and Use of Labo-
ratory Animals.
Synthetic peptides
Peptides were synthesized and puriﬁed as described previously (24). Table
1 summarizes the peptides used in this study; L-amino acids are represented
as capital letters, and D-amino acids as lower-case letters.
Transfectants
BALB/c.3T3 (H-2d) ﬁbroblast transfectants expressing the HIV-1 gp160 of
IIIB isolate (15-12) and control transfectants with selectable marker genes
(Neo) (7, 17) were used for the CTL assay. Murine L-cells (H-2k) transfected
with H-2Dd (T4.8.3) (25), H-2Ld (T.1.1.1) (25), and H-2Kd (B4III2) (26)
were used to determine the MHC class I restriction of the generated CTL line
and clones.
Monoclonal antibodies
We used ﬂuorescein isothiocyanate-conjugated antimouse CD3 (145-2C11),
abTCR (H57-597), CD4 (RM4-5), and CD8 (53-6.7) monoclonal anti-
bodies (PharMingen, San Diego, CA) to determine the cell surface mole-
cules of the established CTL lines and clones.
CTL lines and clones
The P18-I10-speciﬁc CTL line, LINE-IIIB, was generated as described
previously (7). Based on a previously reported procedure (23), a CTL line
speciﬁc for I10(325v) was generated from spleen cells of BALB/c mice
immunized with I10(325v)-pulsed splenic dendritic cells. Brieﬂy, immune
spleen cells were restimulated in vitro with mitomycin C-treated I10(325v)-
pulsed syngeneic BALB/c.3T3 ﬁbroblasts in 24-well culture plates con-
taining 1.5 ml of complete T-cell medium composed of RPMI 1640 medium
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supplemented with 2 mM L-glutamine, 50 mM 2-ME, 100 U/ml penicillin,
100 mg/ml streptomycin, 10% heat-inactivated FCS, and 10% Rat T-STIM
(Collaborative Biomedical Products, Bedford, MA). To establish CTL lines,
the generated CTLs were maintained by biweekly stimulation with the mito-
mycin C-treated I10(325v)-pulsed Neo and were termed LINE-IIIB(325D)
cells. CTL clones were established from bulk CTL lines using a limiting
dilution technique in 96-well U-bottomed microplates, as described pre-
viously (15).
CTL assay
The cytolytic activity of the CTL lines and clones was measured, as pre-
viously described (27), using a standard 5-h 51Cr-release assay with various
51Cr-labeled targets, as indicated in the ﬁgure legends.
Flow cytometric analysis
Flow cytometric analysis was performed to determine the surface molecule
expression of the established CTL lines and clones using a FACScan
analyzer (Becton Dickinson Immunochemical Systems, Mountain View,
CA). We harvested 53 105 cells, washed them twice with serum-free RPMI
1640, and then pelleted them. Fluorescein isothiocyanate-conjugated mono-
clonal antibodies were added to pellets, and they were then incubated for
30 min at 4C. Then, the cells were washed three times and resuspended
with phosphate-buffered saline (PBS) containing 0.1% bovine serum albu-
min and 0.1% sodium azide. Dead cells were gated out by forward and side
scatter based on propidium iodide uptake. Ten thousand events were
acquired for each sample and analyzed using Cell Quest software (Becton
Dickinson, Franklin Lakes, NJ).
mRNA extraction, reverse transcription, and
PCR ampliﬁcation
Poly(A) tail-bearing mRNA was isolated from CTL clones using the Fast
Track mRNA Isolation Kit (Invitrogen, Carlsbad, CA) according to the
manufacturer’s instructions. Reverse transcription and PCR ampliﬁcation
of puriﬁed mRNA were performed with a GeneAmp RNA PCR Kit (PE
Biosystems, Foster City, CA). For the synthesis of T-cell receptor Vb-
speciﬁc cDNA, Vb7-speciﬁc primer (ACATCCCTAAAGGATACAGGG)
and Vb8-speciﬁc primer (ATATCCCTGATGGGTACAAGG) were used in
conjunction with Cb primer (CCGATGGGAGCACACGAACCCTTAAG).
For the synthesis of T-cell receptor Va-speciﬁc cDNA, Va2-speciﬁc primer
(AGCAATTCTGAACTGCAGTTA), Va3-speciﬁc primer (CAGCCCGA-
TGCTCGCGTCACT), and Va16-speciﬁc primer (ATGGACTGTGTGTA-
TGAAAC) were used in conjunction with Ca primer (ACTGGACCACA-
GCCTCAGCGTC).
DNA sequence analysis
PCR products were separated by electrophoresis on a 1% of agarose gel and
sliced bands were puriﬁed by EASYTRAP glass powder (Takara Bio., Siga,
Japan). We then analyzed the puriﬁed DNA by a direct-sequence technique,
using the ABI PRISM Big Dye Terminator Cycle Sequencing FS Ready
Reaction Kit (PE Biosystems), and we analyzed the sequences on the ABI
PRISM 377XL DNA Sequencing System (PE Biosystems).
Molecular modeling
Because the actual 3D TCR structures for both Vb7 and Vb8.3 were un-
known, we carried out comparative and homology modeling to elucidate the
spatial relation between TCRb (Vb7 or Vb8.3) and P18-I10 or I10(325v).
Comparative modeling predicts the 3D structure of a given protein sequence
(target) primarily on the basis of its alignment to one or more proteins of a
known 3D structure (templates). It is usually difﬁcult to accurately determine
the 3D structure from a protein sequence by theoretical procedures. How-
ever, because the 3D TCRb structure consists of a sandwich comprising a
four-stranded antiparallel b-sheet and a three-stranded antiparallel b-sheet
that are linked by a disulﬁde bond, and because the core portion was tightly
bound by a hydrogen bond, the 3D structure of the TCRb, especially the
core portion, could be reliably predicted.
Following the above procedure, the so-called threading or 3D template-
matching method (28) could be implemented to select templates. For this
procedure, we used LIBRA (29) (http://www.ddbj.nig.ac.jp/search/libra_
i-e.html) software in which compatible structures of a target sequence are
sought from the structural library chosen from the Protein Data Bank (PDB),
and the target sequence and 3D proﬁle are aligned by simple dynamic
programming. According to the alignment, sequence remounts on the struc-
ture and its ﬁtness are evaluated by the pseudoenergy potential. The scores
are then sorted from the best-matched templates and shown along with their
alignments. Based on the obtained alignments between the template and the
target Vb sequence, a 3D model is calculated by the MODELLER software
(30–33), by which ﬁve 3D models were obtained from ﬁve templates used.
To examine the interaction between the calculated TCR and P18-I10,
TCR/peptide/class I MHC complex (PDB code 1kj2) was used for two
reasons. First, the 3D structure of the MHC part of 1kj2 is almost identical to
that of MHC used in our experiment, which is also resolved (code 1bii) and
shows a H-2Dd class I MHC molecule presenting the HIV-derived peptide
TABLE 1 Sequences of substituted peptides used in this study
Peptide Sequence*
Residue No. 315 325 329
P18IIIB R I Q R G P G R A F V T I G K
P18-I10 R G P G R A F V T I
I10(325I) I
I10(325L) L
I10(325A) A
I10(325Y) Y
I10(325F) F
I10(325H) H
I10(325T) T
I10(325S) S
I10(325E) E
I10(325K) K
I10(325R) R
I10(325P) P
I10(318r) r
I10(320p) p
I10(322r) r
I10(323a) a
I10(324f) f
I10(325v) v
I10(326t) t
I10(327i) i
I10(325v) R G P G R A F v T I
I10(325i) i
I10(325l) l
I10(325a) a
I10(325y) y
I10(325f) f
I10(325h) h
I10(325t) t
*Sequences of substituted peptides are derived from and aligned with the
sequence of P18-I10, an immunodominant epitope of HIV-1 gp160
envelope glycoprotein of the IIIB strain for the H-2Dd-restricted murine
CTL. In these peptides, L-amino acids are expressed as capital letters and
corresponding D-amino acids are expressed as small letters.
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P18-I10 (RGPGRAFVTI) (34). The amino acid sequence identity between
1kj2 and 1bii is ;90%. Second, 1kj2 is a TCR/peptide/MHC complex (5),
whereas 1bii is only a peptide/MHC complex. In our 3D models, Vb7 or
Vb8.3 was ﬁtted to the TCRb position in 1kj2 and was drawn by Mol Feat
software (FiatLux, Tokyo, Japan).
Quantum chemical calculation
To study the effect of electric charge on the TCR recognition response, we
calculated both the electronic state of P18-I10 and any changes therein based
on a single amino acid substitution (325V with 325T) within the P18-I10
using the PM5 molecular orbital method (MOPAC2002) (35). In this calcu-
lation, hydrogen atoms were ﬁrst added to the PDB 3D structures, and then
the net charges of all atoms in them were obtained, with the PDB 3D stru-
cture being maintained.
RESULTS
Effect of a single amino acid substitution at
position 325 within P18-I10 on
LINE-IIIB recognition
First, to see the effect of a single amino acid substitution at
position 325 where epitope speciﬁcity for LINE-IIIB recog-
nition is determined, a series of P18-I10-derived peptides
shown in Table 1 have been synthesized. Similar to our
previous ﬁndings (10), we conﬁrmed that LINE-IIIB cross-
reacted with an aliphatic residue, such as I, L, or A at posi-
tion 325, in addition to reacting with the original residue V.
Moreover, LINE-IIIB cross-reacted with positively charged
residues such as R and H but not with the negatively charged
E or the uncharged T, S, or P at position 325 (Fig. 1 A). Here,
we should focus on the case of T, because the 3D structure
of the side chain of T is very similar to that of V. When only
one carbon atom of the side chain of V is exchanged for
one oxygen atom (Fig. 1 B; red), the amino acid becomes T,
except for the hydrogen atoms. According to the quantum
chemical calculation using Hamiltonian PM5, the net charge
of the carbon atom in V was about0.3e, whereas that of the
oxygen atom in T is about0.4e; e represents the elementary
charge. This may be the reason why the recognition of V at
position 325 by LINE-IIIB was dramatically changed by
substitution with T. These results indicate that the charges of
the amino acids within the epitope may affect the interaction
between TCRs and peptide/MHC complexes.
FIGURE 1 Effect of a single amino acid substitution at position 325
within P18-I10 on LINE-IIIB recognition. (A) Ten thousand of P18-I10-
speciﬁc CTL line (LINE-IIIB cells) were added to 5000 51Cr-labeled BALB/
c.3T3 ﬁbroblast target cells in the presence of 3 mM of the substituted
peptides at position 325 within P18IIIB, as shown in Table 1. Standard
errors of the means of triplicate cultures were,5% of the mean in each case.
Results are representative of three independent experiments. (B) Ball-and-
stick model of peptide P18-I10. The amino acid side chain containing the
valine (V) at position 325 within P18-I10 and threonine (T) are shown in the
circle. Carbon, oxygen, nitrogen, and hydrogen are shown in gray, red, blue,
and white, respectively.
FIGURE 2 Effect of a single amino acid substitution with D-amino acid
within an epitope peptide, P18-I10, on LINE-IIIB recognition. Ten thousand
LINE-IIIB cells were added to 5000 51Cr-labeled BALB/c.3T3 ﬁbroblast
target cells in the presence of 3 mM of the substituted peptides with a single
amino acid substitution by D-amino acid at each corresponding site (repre-
sented by lower-case letters in Table 1). Standard errors of the means of
triplicate cultures were,5% of the mean in each case. Each experiment was
performed at least three times.
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Effect of a single amino acid substitution
with D-amino acid within an epitope peptide,
P18-I10, on LINE-IIIB recognition
Second, to examine the effect of amino acid substitution with
the same weight and charged D-amino acid on LINE-IIIB
recognition, a series of P18-I10-derived peptides with a
single amino acid substitution by D-amino acid at each
corresponding site represented by small letters in Table 1 has
also been synthesized. When the corresponding D-amino
acid was substituted at position 324, 325, 326, or 327, the
cytotoxic activity of LINE-IIIB was markedly reduced when
compared with other substituted peptides (Fig. 2). This
ﬁnding suggests that CTL-TCRs can strictly recognize each
amino acid within the C-terminal half of the epitope peptide,
including at position 325, which is critical for determining
epitope speciﬁcity, and this is in contrast to their poor ability
to recognize each amino acid within the N-terminal half.
Induction of CTL line and clones speciﬁc for
L-valine or D-valine at position 325 within P18-I10
Then, to study the detailed molecular interactions in deter-
mining T-cell speciﬁcity, we attempted to generate a CTL
line speciﬁc for I10(325v) having a single D-type amino acid
substitution in P18-I10 at position 325 using immunization
of BALB/c mice with syngeneic splenic dendritic cells
pulsed with the peptide (23). The I10(325v)-speciﬁc CTL
line, LINE-IIIB(325D), was successfully established. Al-
though LINE-IIIB(325D) showed some cross-reactivity to
P18-I10 in a dose-dependent manner, it was highly speciﬁc
for I10(325v) (Fig. 3 A). Similarly, LINE-IIIB had some
cross-reactivity to I10(325v)-sensitized targets (Fig. 3 B).
Using limiting dilution techniques described elsewhere
(17), we successfully established two clones, IIE11(D) and
IIA4(D), predominantly speciﬁc for I10(325v) but not for
P18-I10 from LINE-IIIB(325D) cells (Fig. 3 C) as well as
two P18-I10-speciﬁc CTL clones, IIH7(L) and IB9(L), from
the LINE-IIIB cells (Fig. 3 D). Thus, we had established four
highly speciﬁc clones, two of which were speciﬁc for the
D-type of valine (v), and the other two for the L-type of valine
(V) at position 325 within P18-I10.
Speciﬁcity and characterization of the
established CTL clones
We further examined the ﬁne speciﬁcities of the CTL clones
using a series of substituted peptides, each with a single
amino acid substitution of either the L- or D-type having an
aliphatic or aromatic structure at position 325 in P18-I10
(Table 1).
Among the D-speciﬁc clones, IIE11(D) did not cross-react
with I10(325I) at all and was strictly speciﬁc for the D-type
FIGURE 3 Comparison of speciﬁcity of the
newly established CTL lines and clones against
two peptides, peptide P18-I10 and I10(325v).
We examined the cytolytic activity of the
following distinct CTL lines and clones using
a 5-h 51Cr-release assay. To test the peptide
speciﬁcity, effector cells and 51Cr-labeled
BALB/c.3T3 ﬁbroblast targets (E/T ratio was
10:1) were incubated in the presence of various
concentrations of either P18-I10 or I10(325v).
(A) LINE-IIIB(325D) speciﬁc for I10(325v)
was used for effector cells. (B) LINE-IIIB
speciﬁc for P18-I10 was used for effector cells.
(C) The CTL clones, IIE11(D) and IIA4(D),
derived from LINE-IIIB(325D) were used as
effector cells. (D) The CTL clones, IIH7(L) and
IB9(L), from LINE-IIIB were used as effector
cells. Standard errors of the means of triplicate
cultures were ,5% of the mean in each case.
Each experiment was performed at least three
times.
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substitution such as I10(325i) and I10(325a) as well as for
the original I10(325v) (Fig. 4 A), whereas IIA4(D) showed a
weak cross-reactivity for both types of isoleucine, I10(325I)
and I10(325i), as well as for the original I10(325v) (Fig. 4 B).
In addition, both of the L-type-speciﬁc CTL clones, IIH7(L)
and IB9(L), cross-reacted with I10(325I) as well as with the
original P18-I10 (Fig. 4, C and D). These ﬁndings indicate
that the CTL clones can speciﬁcally distinguish the optical
isomers at position 325.
Because P18-I10-speciﬁc CTL and their clones are CD81,
Dd-class I MHC molecule-restricted conventional abT
lymphocytes, we next conﬁrmed the surface molecules and
MHC-restriction of the I10(325v)-speciﬁc line and clones.
LINE-IIIB(325D) and two clones, IIE11(D) and IIA4(D),
were all CD31, CD4, CD81, and TCRab1 by FACS anal-
ysis (data not shown), and they did not show any cytotoxicity
against NK-sensitive YAC-1 cells (data not shown). More-
over, using three L cell (H-2k) transfectants expressing the
class I MHC of the d-haplotype, T4.8.3 (Dd), T1.1.1 (Ld),
and B4III2 (Kd) (25,26), we conﬁrmed that the I10(325v)-
speciﬁc CTL line and clones were restricted by the Dd class I
MHC molecule (data not shown).
TCR-sequences of the established clones
Taken together, the two groups of CTL clones with high
speciﬁcity to the substituted P18-I10-derived peptides, having
either the L-type of valine (V) or D-type of valine (v) at posi-
tion 325, expressed both CD8 and ab TCRs, and were
restricted by the same class I MHC molecule, Dd. Therefore,
taking advantage of the unique combinations of CTL clones,
we attempted to perform a precise analysis of the interaction
between the TCRs of those clones and the amino acid at
FIGURE 4 Effects of a single amino
acid substitution at position 325 within
P18-I10 on target sensitization for CTL
recognition. We measured the cytolytic
activity of the CTL lines and clones
using a 5-h 51Cr-release assay. For the
analysis of ﬁne peptide speciﬁcity,
effector cells and 51Cr-labeled BALB/
c.3T3 ﬁbroblast targets were mixed
with 10 mM of each substituted peptide.
The following four clones were used as
effectors (E/T ratio was 20:1): (A) clone
IIE11(D), (B) clone IIA4(D), (C) clone
IIH7(L), and (D) clone IB9(L). Standard
errors of the means of triplicate cultures
were ,5% of the mean in each case.
Each experiment was performed at least
three times.
FIGURE 5 Nucleotide and amino acid sequences that form the V(D)J
region of the TCRa and -b chain from the established CTL clones. We
analyzed the amino acid sequences of TCRs in two groups of CTL clones
with high speciﬁcity to substituted P18-I10-derived peptides, having either
the D-type of valine (v) (IIE11(D) and IIA4(D)) or the L-type of valine (V) at
position 325 (IIH7(L) and IB9(L)) restricted by the same class I MHC
molecules, Dd.
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position 325 within epitope to determine the speciﬁcity by
comparing their TCR sequences.
To investigate the actual amino acid sequences of the
TCRs in the CTL clones, we extracted their mRNA and
analyzed the nucleotide sequences of the a- and b-chain
transcripts after a cDNA synthesis and PCR ampliﬁcations.
The Va usage of the I10(325v)-speciﬁc clones, IIE11(D) and
IIA4(D), were both Va16 (36), whereas that of the P18-I10-
speciﬁc clones, IIH7(L) and IB9(L), were Va3 (37) and Va2
(BLASTN Accession U88296), respectively (Fig. 5). It
should be noted that all of the four distinct clones used the
same uncommon Ja gene segment, 18BBM142, determined
from a murine alloreactive T-cell hybridoma speciﬁc for
I-Abm12 (38). In contrast, the Vb usage of the 325(v)-speciﬁc
clones, IIE11(D) and IIA4(D), was Vb8.3 (39) with the Jb 2.2
segment (40) bearing the same CDR3, ‘‘DWGGS,’’ whereas
the Vb usage of the 325(L)-speciﬁc clones, IIH7 and IB9,
was Vb7 with the Jb1.1 segment (41) encoding a distinct
sequence, ‘‘LGYT’’ and ‘‘LGVT,’’ respectively, in the CDR3
ﬂap (Fig. 5). These results strongly indicate that the TCRb
chains of those clones may be responsible for the speciﬁcity
of the epitope.
Identiﬁcation of the interaction site between the
TCRs and a critical amino acid at position 325 to
determine epitope speciﬁcity by molecular
modeling analysis
Based on the above ﬁndings, we then studied the site that
determines the epitope speciﬁcity of the TCRb chain in the
CTL clones using a 3D molecular modeling analysis (see
Materials and Methods). We used the LIBRA software
(29,42) to select ﬁve compatible templates with excellent
Standardized Scores (SD value) for both Vb7 and Vb8.3
(Fig. 6 A). Fig. 6 B shows the alignment of the ﬁve most
suitable templates for each TCR.
We then used the MODELLER software (30,31,33) to
model the 3D structure of the TCR. First, to conﬁrm the
FIGURE 6 (A) Compatible templates with
excellent Standardized Scores (SD value) for
both Vb7 and Vb8.3 selected from the LIBRA
software. Bold abbreviations are deﬁned as
follows: Rk, rank position; StrC, structural
code of PDB (the last character is a subunit
name); Lsr, length of the structural template;
Lal, length of the aligned region; Rsc, raw
score of the structural template; SD, standard-
ized score; Rs/N, raw score (Rsc) normalized
by the alignment length (Lal); ID%, sequence
identity. (B) Sequence alignment of TCR Vb7,
Vb8.3, and each of the ﬁve template proteins
(1a6wH, 1dn0D, 1tcrA, 1ao7D, 1kb5A for
Vb7 and 1hxmB, 1etzB, 1fo0A, 1h5bA, 1d1fL
for Vb8.3) obtained from the LIBRA software.
In this ﬁgure, the amino acid sequences of
CDR1 and CDR3 from TCR Vb7 or Vb8.3 are
drawn in red and green, respectively. In 10
template proteins, the corresponding portion of
the CDR1 and CDR3 regions are also drawn in
red and green, respectively. Conserved cysteine
residues upstream of CDR1 and CDR3 are
drawn in magenta. Two or three amino acids
between the conserved cysteine residues and
CDR1 are drawn in blue (see Discussion).
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accuracy of our molecular modeling method, we predicted
the 3D structure of a previously analyzed protein using
MODELLER and then compared it with the experimental 3D
structure obtained from x-ray crystallographic analysis for
the same protein. We selected two proteins (PDB cord
1dn0D and 1a6wH) having high scores in Fig. 6 A and then
calculated the 3D structure of 1dn0D using 1a6wH as a
template. As shown in Fig. 7, the 3D structure of 1dn0D
obtained from MODELLER was similar to that obtained
experimentally, and their core regions were nearly identical.
These results suggest that our molecular modeling method
could be useful for the structural analysis of unknown TCRs.
We next predicted the 3D structures of TCR Vb7 and
Vb8.3 and analyzed their interactions with P18-I10. The
obtained 3D structures for Vb7 using the ﬁve selected
templates were quite similar (Fig. 8, A–D) and could be
conﬁrmed by rotating the calculated structures from various
angles (data not shown). In addition, each obtained 3D
structure for Vb7 was ﬁtted to the TCRb part in 1kj2 to
analyze the interaction with the P18-I10 peptide. Although
both the CDR1 (blue) and CDR3 (red) in Vb7 appeared to
interact with the C-terminal half of P18-I10, the critical site
for determining epitope speciﬁcity (325V, bright green)
within P18-I10 was found to be more closely associated with
the canonical free bottom portion of CDR1 and not with the
CDR3 loop (Fig. 8, A and B): the CDR3 loop is too far from
325V. However, when the 325V was substituted with 325v
(bright red), the CDR1 loop of Vb7 might come in contact
with the 325v (Fig. 8, C and D), which seemed to induce
conformational interference between the TCR and I10(325v),
and thus, the H-2Dd-restricted peptide I10(325v) would not
be recognized by the P18-I10-speciﬁc clones, IIH7(L) and
IB9(L). These results are consistent with our experimental
results and indicate that the CDR1 loop of TCR Vb7 should
be the key site for determining P18-I10 speciﬁcity in the
interaction with the L-valine at position 325.
Similarly, the molecular modeling for Vb8.3 was per-
formed using another ﬁve of the most suitable templates
shown in Fig. 6 A; each of these actual sequences is shown in
Fig. 6 B. The calculated 3D structures of Vb8.3 based on the
ﬁve templates had almost the same features (Fig. 8, E–H) as
seen in the case of Vb7. In contrast to the case of Vb7, 325v
(bright red) seemed to be associated with the free bottom
portion of the CDR1 loop of Vb8.3 but not with the CDR3
loop of Vb8.3 (Fig. 8, E and F). However, the distance
between the 325V (bright green) and the CDR1 loop in the
case of Vb8.3 appeared to be greater than that in the case of
Vb7 (Fig. 8, G and H), which can make a good contact with
the 325V in P18-I10.
To substantiate the interaction between valine at position
325 and TCR-CDR1, the distance between terminal atoms
in the side chain of amino acids within the epitope peptide
and atoms in the main chain of the nearest portion within
the TCR was calculated. As shown in Table 2, ﬁrst to con-
ﬁrm the reliability of our molecular modeling, the distance
between the two terminal atoms (OD1 and OD2) in the side
chain of the seventh amino acid, aspaltic acid (D), within
epitope peptide pKB1(aa: KVITFIDL) and the nearest por-
tion in the TCR from OD1 or OD2 was determined using an
already reported TCR/peptide/MHC complex, 1kj2 (PDBcode)
obtained from x-ray crystallographic analysis (5). Based on
the above observation, the distance between the two terminal
atoms (CG1 and CG2) in the side chain of 325V or 325v and
their surrounding atoms in the main chain of the obtained
TCRs, Vb7 and Vb8.3, calculated (Tables 3 and 4) and
compared with that of 1kj2. The results indicate that the
distance between 325V and CDR1 in Vb7 is similar to the
distance in the case of 1kj2, whereas the distance between
325v and CDR1 in Vb7 is too small, which may induce
conformational interference between them. In contrast, the
distance between 325v and CDR1 in Vb8.3 is similar to
1kj2, but the distance between the 325V and the CDR1 in
Vb8.3 appeared to be too far from that of 1kj2. These results
again agreed with our experimental results that Vb8.3
recognized the epitope I10(325v) having D-valine at position
325 via CDR1 but did not recognize the P18-I10 containing
L-valine at that position.
FIGURE 7 Comparison between the predicted 3D structure for 1dn0D by
the MODELLER software and that of the same protein registered in PDB.
The 3D structure of the protein (PDB cord 1dn0D) was predicted by the
MODELLER, a molecular modeling software, using a protein (e.g., PDB
cord 1a6wH) as a template. The predicted 3D structure for 1dn0D is drawn
in blue, and the PDB 3D structure is drawn in red. Their backbone represen-
tations in the molecular modeling are drawn from rotated two distinct views
(A and B).
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Therefore, CDR1, but not the CDR3 loop, in Vb7 or
Vb8.3 seems to play an important role in the recognition
of each speciﬁc epitope peptide. Moreover, amino acids at
positions 26 to 31: DMSHET within the CDR1 of Vb7, or
TNSHNY within the CDR1 of Vb8.3, appear to interact with
the critical amino acid at position 325 to determine the
epitope speciﬁcity.
DISCUSSION
In our previous study, we found that the amino acids at
positions 322R and 324F were critical for Dd binding, and
those at position 325V were essential for interacting with
TCRs (8,17). Also, the C-terminus 327I appears to be a key
amino acid for Dd binding to form the Dd-binding motif
(8,18). In this study,we demonstrated that the substitution of a
positively charged 322R by 322r did not result in measurable
changes in target sensitization, although in our previous
study the substitution with uncharged alanine (A) completely
eliminated the capacity to sensitize the targets (17), indicating
that a positive electric chargemust be critical for Dd binding at
position 322, and that a reduction of charge in the amino acid
might diminish the epitope potency for T-cell activation. As
shown in Fig. 1B, the side chains ofV andT have the same 3D
FIGURE 8 3D structures representing the
interaction between TCR Vb7 (Vb8.3) and
P18-I10/H-2Dd Complex or the interaction
between TCR Vb7 (Vb8.3) and I10(325v)/
H-2Dd complex. (A–H) The ternary complex of
TCR Vb7 or Vb8.3 onto either P18-I10 or
I10(325v) bounded to the H-2Dd class I MHC
molecules were illustrated by computer-based
molecular modeling (see Materials andMethods).
Horizontal gray backbone represents the H-2Dd
class I MHC molecule, and the yellow ball
format indicates the Dd-bounded epitope pep-
tide P18-I10. Vertical overlapping white back-
bones indicate either TCR Vb7 or Vb8.3. In
these ﬁgures, Vb7 and Vb8.3 made from ﬁve
distinct template proteins were overlaid in one
ﬁgure. The CDR1 and CDR3 loops from both
TCR Vb chains are drawn in cyan and red,
respectively. The L-type of valine (V) and the
D-type of valine (v) at position 325, where
epitope speciﬁcity appears to be determined,
are shown in bright green and bright red,
respectively. The 3D-structures of the (A) Vb7
/H-2Dd/P18-I10, (B) enlarged ﬁgure of A, (C)
Vb7 /H-2Dd/I10(325v), (D) enlarged ﬁgure of
C, (E) Vb8.3 /H-2Dd/I10(325v), (F) enlarged
ﬁgure of E, (G) Vb8.3/H-2Dd/P18-I10, and (H)
enlarged ﬁgure of G are shown in eight
independent panels.
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structure, except for the hydrogen atoms, if one terminal
carbon atom of the side chain of V is exchanged for one
oxygen atom. According to the quantum chemical calcula-
tion, the net charge of the carbon or the oxygen is 0.3e or
0.4e, respectively. In addition, three hydrogen atoms,which
have positive charges, are added to the carbon, whereas one
hydrogen atom is added to the oxygen. Thus, T generates a
greater negative net charge than V. The inﬂuence of this
charge difference was evident when LINE-IIIB recognized
the peptide. It is likely that T had a greater repulsive force
against the oxygen atoms in the CDR1 loop comparedwith V.
This repulsive force may account for the signiﬁcant reduction
in the recognition byLINE-IIIB after substitutionwithT.These
ﬁndings indicate that the charge of an amino acid at a speciﬁc
position within an epitope can affect its binding capacity to
MHC molecules and/or the interaction with a TCR.
Although the method we applied here for modeling the
TCR/peptide/class I MHC complex was not directly based
on crystallographic analysis, our computer-based molecu-
lar modeling was still accurate. Indeed, as demonstrated in
Fig. 7, the predicted 3D structure for 1dn0D byMODELLER
was similar to that determined experimentally, and the core
regions appeared to be nearly identical. This reﬂects the fact
that the 3D structures of the core regions of the TCR consist
of a four-stranded antiparallel b-sheet and a three-stranded
anti-parallel b-sheet linked by a disulﬁde bond. Although the
predicted 3D structure of CDR3 seems slightly different
from the experimental 3D structure of CDR3 because of
the large loop, the predicted 3D structure of CDR1 appears
almost the same as the experimental 3D structure. These
results suggest that the TCR domain predicted by the present
molecular modeling methods can become useful and reliable
tools for the structural analysis of TCRs.
In these sorts of structural analyses, it should be ac-
knowledged that a substitution of D-valine (v) for L-valine
(V) would result in a conformational interference between
the class I MHC molecule and the D-valine (v), which itself
could decrease the recognition response by LINE-IIIB.
However, as shown in Fig. 9, no conformational interference
occurred in this study. Thus, I10(325v) would also be asso-
ciated with the class I MHC molecule so that TCRs may
recognize the epitope. Therefore, our ﬁndings suggest that
the change in the recognition response by LINE-IIIB after
the D-valine (v) substitution reﬂects the interaction with the
TCR.
Our molecular modeling analysis demonstrated that the
critical area of the TCR for interacting with 325Vwithin P18-
I10 was the peptide DMSHET, within the CDR1 of Vb7. In
contrast, the substituted peptide with the D-type amino acid,
I10(325v), was recognized by the peptide TNSHNY within
the CDR1 of Vb8.3. Therefore, the CDR1 in the Vb7 or
Vb8.3might play an important role in recognizing the epitope
P18-I10 or I10(325v), respectively, and, in particular, the
distance between CDR1 and the amino acid 325V or 325v
within the peptide seemed to be essential for recognizing the
epitope. Taken together, the results derived from our molec-
ular modeling strategy appear to be consistent with the
experimental results.
Although the epitope speciﬁcity created by TCRs has been
reported to be dependent mainly on the amino acid sequences
in the CDR3 regions for both the TCRa and b chains (43,44),
crystallographic analyses on various TCR and peptide/MHC
interactions have suggested that both the CDR1 and CDR3 in
TABLE 2 The distance between two terminal atoms in the side chain of the seventh amino acid, Asp (D) within epitope peptide and
atoms in main chain of the nearest portion within the TCR
N (S28) Ca (S28) C (S28) O (S28) N (Q29) Ca (Q29) C (Q29) O (Q29) N (Y30) Ca (Y30) C (Y30) O (Y30)
OD1 10.86 9.55 8.37 7.24 8.76 7.98 7.60 6.99 8.27 8.39 8.29 9.37
OD2 8.83 7.48 6.40 5.24 6.97 6.44 6.21 5.91 6.76 7.08 6.84 7.88
Unit of the distance is A˚. The values are calculated using 1kj2 (PDB code), which is TCR/peptide/ MHC complex structure obtained from x-ray
crystallographic analysis. The OD1 or OD2 represents the terminal atom of the side chain in the seventh amino acid, aspaltic acid (D), within epitope peptide
pKB1(aa: KVITFIDL). The amino acids Ser 28 (S28), Gln 29 (Q29), and Tyr 30 (Y30) are the nearest portion within the TCR from the OD1 or OD2.
TABLE 3 The distance between two terminal atoms in the side
chain of 325V or 325v and atoms in main chain of the obtained
TCR-CDR1 through molecular modeling
Vb7 N(S) Ca(S) C(S) O(S) N(H) Ca(H) C(H) O(H)
1a6wH CG1(325V) 10.20 9.55 8.56 8.52 7.99 7.08 7.85 7.48
CG2(325V) 9.57 8.88 7.62 7.41 7.01 5.80 6.17 5.57
1dn0D CG1(325V) 10.03 9.43 8.73 8.11 9.12 8.90 9.30 9.33
CG2(325V) 9.40 8.79 7.77 6.99 8.06 7.58 7.65 7.48
1tcrA CG1(325V) 7.69 6.38 6.49 7.45 5.86 6.44 7.84 8.34
CG2(325V) 6.63 5.41 5.09 5.76 4.51 4.80 6.29 6.97
1ao7D CG1(325V) 7.57 6.48 7.18 6.85 8.40 9.21 9.59 10.11
CG2(325V) 6.91 5.63 5.85 5.34 6.96 7.48 7.89 8.63
1kb5A CG1(325V) 7.51 8.02 7.58 6.44 8.67 8.81 9.71 10.44
CG2(325V) 6.77 7.06 6.21 4.99 7.08 6.92 7.89 8.79
1a6wH CG1(325v) 8.10 7.48 6.70 6.85 6.20 5.60 6.69 6.63
CG2(325v) 6.95 6.27 5.12 5.09 4.53 3.56 4.38 4.18
1dn0D CG1(325v) 7.94 7.34 6.88 6.41 7.39 7.47 8.10 8.42
CG2(325v) 6.79 6.16 5.28 4.59 5.73 5.59 5.91 6.14
1tcrA CG1(325v) 6.51 5.12 5.35 6.50 4.59 5.40 6.57 6.84
CG2(325v) 5.01 3.61 3.26 4.28 2.35 3.02 4.34 4.78
1ao7D CG1(325v) 5.64 4.73 5.73 5.63 6.98 8.02 8.36 8.66
CG2(325v) 4.39 3.09 3.63 3.36 4.88 5.73 6.12 6.61
1kb5A CG1(325v) 5.60 6.21 6.12 5.18 7.37 7.86 8.74 9.24
CG2(325v) 4.21 4.55 4.02 2.91 5.16 5.49 6.49 7.13
Unit of the distance is A˚. The code 1a6wH, 1dn0D, 1tcrA, 1ao7D, or
1kb5A represents each template protein to determine the structure of Vb7.
CG1 and CG2 are two terminal atoms of side chain in 325V or 325v. The suc-
cessive two amino acids, Ser and His, within CDR1 of Vb7 are the nearest
portion for CG1 or CG2.
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the TCRa and TCRb chains might contact with the antigenic
peptide/MHC complex (1,2,5,6), particularly with the car-
boxyl-terminal portion of the peptides (2). Moreover, recent
reports have shown that the CDR1 in Vb10 participated in
class I MHC molecule-mediated T-cell recognition (45,46).
In these reports, signiﬁcant alteration in the capacity to bind
class I MHC molecules and in the ability to respond to the
peptide/MHC complex was demonstrated when a single
amino acid substitutionwas introduced into theCDR1of TCR
Vb10 by site-directed mutagenesis. Indeed, we have shown
here that the CDR1 in the TCRb chains appeared to interact
directly with the key amino acid for determining epitope
speciﬁcity. Thus, if the most critical amino acid for deter-
mining the epitope speciﬁcity is located near the C-terminal
portion of a peptide such as P18-I10, not only the CDR3 but
also the CDR1 in the TCRb chain may be involved in
determining antigen speciﬁcity.
It is also important to consider the role of the primary
structures in TCR recognition. As demonstrated in Fig. 6 B,
there are two cysteine (C) residues positioned upstream of
CDR1 (magenta) and CDR3 (magenta) of both TCR Vb7
and Vb8.3. These residues bind each other via a disulﬁde
bond and must be a basic structure of TCRs because they are
conserved in most of the murine TCR sequences (47) . The
two or three amino acids (blue) between the conserved
cysteine (C) residues and the CDR1 would be key amino
acids in forming the 3D structure of CDR1, although they do
not interact directly with the epitope peptide. If only these
amino acids are exchanged for other amino acids, the 3D
structure of CDR1 affecting the recognition of an amino acid
at position 325 would change. Indeed, these amino acids are
TABLE 4 The distance between two terminal atoms in the side chain of 325V or 325v and atoms in main chain of the obtained
TCR-CDR1 through molecular modeling
Vb8.3 N(T) Ca(T) C(T) O(T) N(N) Ca(N) C(N) O(N) N(S) Ca(S) C(S) O(S)
1hxmBCG1(325V) 13.34 12.22 11.94 12.32 11.47 11.47 10.62 9.61 11.19 10.74 11.80 12.32
CG2(325V) 12.54 11.59 11.25 11.41 11.00 10.98 9.90 8.83 10.34 9.64 10.65 11.36
1etzBCG1(325V) 13.77 13.45 12.19 11.26 12.24 11.31 9.99 8.95 10.16 9.20 9.41 10.25
CG2(325V) 13.14 12.75 11.63 10.76 11.76 11.02 9.57 8.73 9.41 8.22 8.32 9.30
1fo0ACG1(325V) 10.43 9.82 9.37 9.20 9.43 9.34 10.58 11.43 10.85 12.07 13.27 13.89
CG2(325V) 9.41 8.58 8.29 8.45 8.18 8.25 9.66 10.47 10.12 11.47 12.47 13.09
1h5bACG1(325V) 11.98 10.99 10.34 10.13 10.23 9.81 10.97 12.02 10.95 12.14 12.24 11.29
CG2(325V) 11.18 10.43 9.87 9.95 9.52 9.16 10.18 11.13 10.20 11.29 11.10 10.02
1dlfLCG1(325V) 12.46 11.35 10.28 9.72 10.18 9.27 10.19 11.40 9.77 10.82 11.61 11.18
CG2(325V) 11.39 10.46 9.42 9.14 9.06 8.14 9.06 10.25 8.69 9.75 10.28 9.64
1hxmBCG1(325v) 11.19 10.04 9.53 9.84 8.98 8.81 7.89 6.96 8.39 7.95 9.00 9.47
CG2(325v) 10.21 9.16 8.72 8.95 8.37 8.32 7.31 6.25 7.84 7.33 8.47 9.12
1etzBCG1(325v) 11.63 11.33 10.01 9.08 10.05 9.08 7.83 6.75 8.15 7.37 7.76 8.53
CG2(325v) 10.57 10.17 9.00 8.11 9.13 8.38 6.95 6.11 6.87 5.78 6.11 7.09
1fo0ACG1(325v) 8.55 8.16 7.68 7.31 7.99 7.98 9.10 9.82 9.44 10.57 11.78 12.26
CG2(325v) 6.96 6.31 6.03 6.03 6.22 6.47 7.78 8.44 8.38 9.66 10.67 11.12
1h5bACG1(325v) 9.98 8.91 8.17 7.84 8.17 7.74 8.99 10.05 9.05 10.33 10.63 9.80
CG2(325v) 8.70 7.89 7.22 7.27 6.92 6.57 7.69 8.66 7.83 9.04 9.03 8.07
1dlfLCG1(325v) 10.66 9.50 8.36 7.65 8.40 7.51 8.42 9.61 8.05 9.15 10.11 9.84
CG2(325v) 9.11 8.13 6.97 6.57 6.70 5.75 6.71 7.91 6.41 7.59 8.30 7.82
Unit of the distance is A˚. The code1hxmB,1etzB, 1fo0A,1h5bA,or 1dlfL represents each template protein todetermine the structure ofVb8.3.CG1andCG2are two
terminal atoms of side chain in 325V or 325v. The successive three amino acids, Thr, Asn, and Ser, within CDR1 of Vb8.3 are the nearest portion for CG1 or CG2.
FIGURE 9 (A andB) 3Dstructures ofP18-I10/H-2Ddcomplex and I10(325v)/
H-2Dd complex. Gray ribbon and ball format represent the H-2Dd class I MHC
molecule, and the yellow ball format indicates the Dd-bounded epitope peptide,
P18-I10 or I10(325v). In the H-2Dd class IMHCmolecule, only the positions for
interactionwith 325V are drawn in the ball format, for clarity. The L-type of valine
(V) and the D-type of valine (v) at position 325 are shown in green and red, re-
spectively. Radius of ball format indicates van der Waals radius.
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highly variable for both TCR Vb7 and Vb8.3 (Fig. 6 B) and
for various other murine TCR sequences (47), whereas the
regions just after CDR1 are mostly conserved. These amino
acids are likely to participate in the peptide recognition by
creating small changes in the 3D structure of CDR1. In this
regard, both CDR1 and the two or three amino acids between
the cysteine (C) and CDR1 may play a important role in
recognizing position 325 within P18-I10 or I10(325v).
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